Top Industry Leaders in the Antipsychotic Drugs Market
Latest Antipsychotic Drugs Companies Update
Intra-Cellular Therapies Received FDA approval for Caplyta (lumateperone) as adjunctive therapy for depressive episodes associated with bipolar I or II disorder, expanding its market reach.
Alkermes Announced positive results from ENLIGHTEN-early, a Phase 3b study evaluating LYBALVI for schizophrenia, providing further evidence for its efficacy and tolerability.
Luye Pharma Group Secured FDA approval for Rykindo for the treatment of schizophrenia and bipolar 1 disorder, offering a new option with a once-daily dosing schedule.
Otsuka Pharmaceutical Co., Ltd. and Lundbeck Received FDA approval for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents (13-17 years old), addressing a crucial need in this underserved population.
List of Antipsychotic Drugs Key Companies in the Market
-
Johnson and Johnson (U.S.)
-
GlaxoSmithKline Plc. (U.K.)
-
Pfizer Inc. (U.S.)
-
AstraZeneca (U.K.)
-
Bristol-Myers Squibb (U.S.)
-
Eli Lily & Co. (U.S.)
